Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Progressive Familial Intrahepatic Cholestasis

Liver & Hepatic

Progressive Familial Intrahepatic Cholestasis (PFIC) Clinical Trials

Also called PFIC, Byler disease, cholestatic liver disease

Progressive familial intrahepatic cholestasis (PFIC) encompasses rare autosomal recessive disorders causing progressive cholestasis and cirrhosis in infants and children. Three main types are recognized: PFIC1 results from mutations in ATP8B1 affecting a lipid flippase critical for plasma membrane homeostasis; PFIC2 from ABCB11 mutations affecting the bile salt export pump (BSEP), the major transporter mediating bile acid secretion into bile; and PFIC3 from ABCB4 mutations affecting a phospholipid transporter responsible for phospholipid secretion.

In plain words, progressive familial intrahepatic cholestasis is a group of inherited liver disorders where bile cannot flow out of the liver properly. Bile builds up and slowly damages the liver in childhood, often causing yellow skin and strong itching.

Get an email when new Progressive Familial Intrahepatic Cholestasis trials open or the FDA decides. Get alerts

Progressive Familial Intrahepatic Cholestasis

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 8 studies with no phase, like observational studies, and 1 phase 4 study following medicines after approval.

FDA review0

No decision pending. FDA calendar

FDA-approved medicines2

Bylvay · Livmarli

Progressive Familial Intrahepatic Cholestasis has 2 FDA-approved medicines, 9 open or active clinical trials (9 recruiting), and no pending FDA decision.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

Latest for Progressive Familial Intrahepatic Cholestasis

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Progressive Familial Intrahepatic Cholestasis

These molecular defects impair bile formation and secretion, leading to intrahepatic cholestasis with progressive hepatocellular injury, inflammation, and fibrosis. Patients develop severe cholestasis with jaundice, intense pruritus that severely impacts quality of life, hepatosplenomegaly, failure to thrive, and growth retardation.

Keep reading about Progressive Familial Intrahepatic Cholestasis

Without intervention, most progress to cirrhosis and liver failure requiring transplantation by late childhood or adolescence. According to MedlinePlus Genetics, PFIC2 (BSEP deficiency) carries a higher risk of hepatocellular carcinoma, a liver cancer, and PFIC3 (MDR3 deficiency) a higher risk of cholangiocarcinoma, a bile duct cancer. Laboratory studies reveal elevated aminotransferases, hyperbilirubinemia, and a characteristic pattern of normal or minimally elevated gamma-glutamyl transferase (GGT) in PFIC1 and PFIC2, while GGT is high in PFIC3, which helps distinguish PFIC from other cholestatic disorders.

What are the symptoms of Progressive Familial Intrahepatic Cholestasis?

These are common symptoms of Progressive Familial Intrahepatic Cholestasis, and how strong they are varies from person to person.

  • Jaundice and cholestasis in infancy or childhood
  • Severe pruritus (itching)
  • Hepatosplenomegaly
  • Failure to thrive
  • Progressive liver fibrosis and cirrhosis
  • Portal hypertension in advanced stages

Who gets Progressive Familial Intrahepatic Cholestasis?

Progressive familial intrahepatic cholestasis typically manifests before age 10 years, with earlier onset and more severe phenotypes in PFIC2. The condition affects males and females equally. Since it follows autosomal recessive inheritance, both parents must carry mutations for disease manifestation. Parents are typically asymptomatic carriers.

Prevalence varies by ethnicity and geographic region, PFIC1 was first described as Byler disease in an Amish family, and an ATP8B1 variant is known among the Amish.

Next steps: find trials you might fitsee approved treatmentsget help payingget alerts

Which medicines are FDA-approved for Progressive Familial Intrahepatic Cholestasis?

There are currently 2 FDA-approved medications for Progressive Familial Intrahepatic Cholestasis.

odevixibat
Ipsen Biopharmaceuticals, Inc.
Search
maralixibat chloride
Mirum Pharmaceuticals Inc.
Search

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

How to get help paying for Progressive Familial Intrahepatic Cholestasis treatment

Charity funds and drugmaker programs for Progressive Familial Intrahepatic Cholestasis, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Charity funds
  • From a charity · PFIC Network
    PFIC Financial Assistance Program fund
    Open

    Pays for: Uncovered medical expenses (genetic testing, vitamins, travel), insurance premiums and copays, rent or utilities, up to $1,000 per year.

    The foundation says: “The PFIC Network accepts applications throughout the year on a rolling basis.”
Status as each foundation showed it on November 16, 2026.
Drugmaker programs
Open a medicine for who qualifies, by insurance type.

Every program and fund for Progressive Familial Intrahepatic Cholestasis, by insurance →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Progressive Familial Intrahepatic Cholestasis

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Progressive Familial Intrahepatic Cholestasis resources

Reputable organizations and medical references for learning more about Progressive Familial Intrahepatic Cholestasis, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Progressive Familial Intrahepatic Cholestasis

Use this Progressive Familial Intrahepatic Cholestasis clinical trial finder to see the 9 studies recruiting patients in the United States and worldwide, with eligibility criteria in plain English. Of these, 2 test a treatment and 7 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

9 active trials worldwide
Filter:
Sort:
RecruitingObservational study, no treatment givenRecently updatedNCT06193928

Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)

Intervention: Livmarli, Livmarli

Sponsor: Mirum Pharmaceuticals, Inc.

The objective of this 5-year, prospective, observational cohort study is to evaluate the long-term safety and clinical outcomes of patients with Alagille syndrome (ALGS) or Progressive familial intrahepatic cholestasis (PFIC) treated with Livmarli.

Ages not specified
Started Sep 2023Updated 5 days agoEst. Sep 2028 (~1y 10m)
RecruitingObservational study, no treatment givenRecently updatedNCT07588880

A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in China

Sponsor: Ipsen

This registry-based study will collect information from people with Progressive Familial Intrahepatic Cholestasis (PFIC) who take odevixibat (Bylvay) as part of routine clinical care in China.

Ages 6 Months+
Started Apr 2026Updated 3 weeks agoEst. Apr 2031 (~4y 5m)
RecruitingObservational study, no treatment givenRecently updatedNCT07185919

A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in South Korea

Sponsor: Ipsen

This study will collect information from people with Progressive Familial Intrahepatic Cholestasis (PFIC) as they use odevixibat in their daily lives. Odevixibat is a medicine that helps people with PFIC, a type of rare disease that makes their liver not work well and causes itch...

Ages not specified
Started Oct 2025Updated 3 weeks agoEst. Sep 2032 (~5y 10m)
RecruitingObservational study, no treatment givenRecently updatedNCT07411716

Pediatric Evaluation and Registry for Liver Cholestasis in Canada

Sponsor: Children's Hospital of Eastern Ontario · Mirum Pharmaceuticals, Inc.

The purpose of this study is to create a national, multi-centre registry for children with Alagille syndrome (ALGS) and Genetic Intrahepatic Cholestasis (GIC) that follows participants long-term, ensuring standardized, high-quality data capture across all participating pediatric hepatology centres.

Ages up to 18 Years
Started Apr 2026Updated 1 month agoEst. Mar 2031 (~4y 4m)
RecruitingTreatment trialPhase 4Updated a few months agoNCT07290257

Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU)

Intervention: Livmarli Oral Product

Sponsor: Mirum Pharmaceuticals, Inc.

In patients with Alagille syndrome (ALGS), the key objectives are to evaluate the tolerability, long-term safety (including possible liver toxicity) and long-term efficacy of Livmarli treatment.

Ages 2 Months+
Started Sep 2025Updated 4 months agoEst. Sep 2030 (~3y 10m)
Find Progressive Familial Intrahepatic Cholestasis trials near you, ranked by distance →
Active trial locations8 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.

Trial Pipeline

Feb 2023 to Nov 2031
2024
2026
2028
2030
now
Phase 4
Observational
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Progressive Familial Intrahepatic Cholestasis trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Progressive Familial Intrahepatic Cholestasis foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Progressive Familial Intrahepatic Cholestasis patient communities

Facebook groups, Reddit communities and YouTube channels where Progressive Familial Intrahepatic Cholestasis patients, caregivers and advocacy groups talk.

Companies developing Progressive Familial Intrahepatic Cholestasis treatments

Drugmakers that list Progressive Familial Intrahepatic Cholestasis in their rare disease portfolio, 3 in all.

Questions people ask about Progressive Familial Intrahepatic Cholestasis